Phase 1 N=97 First in Human Study of M4344 in Participants With Advanced Solid Tumors
Solid Tumor · Advanced Solid Tumor
Primary: Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 2; 1; 2; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=20 Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers
HIV Infections
Primary: Safety and Tolerability of PRO 140 — 4; 4; 0; 4 number of subjects reporting AEs
Phase 1 N=12 A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects
Healthy Participants
Primary: Plasma Concentration of BRV and Its Metabolites (Ucb-42145, Ucb-100406-1, ucb107092-1) After Single Dose — NA; 1039; 2610; 2725 nanograms/milliliter (ng/mL)
Phase 1 N=75 A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer
Breast Cancer
Primary: Change From Baseline in Tumor Cell Proliferation, as Measured by the Proportion of Nuclei Staining Ki67-Positive at Surgery Relative to Baseline in Pre- and…
Phase 1 N=32 A Study of TAK-951 in Healthy Adults
Healthy Volunteer
Primary: Number of Participants Who Reported One or More Treatment-emergent Adverse Events (TEAEs) — 1; 0; 1; 3 Participants
Phase 1 N=38 Continuous Infusion of rhIL-15 for Adults With Advanced Cancer
Lymphoma · Carcinoma
Primary: Maximum Tolerated Dose (MTD) of Recombinant Human Interleukin-15 (rhIL-15) for 10 Day Dosing — 2 mcg/kg/day
Phase 1 N=12 Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Recurrent Acute Myeloid Leukemia · Recurrent Myelodysplastic Syndrome
Primary: Number of Participants With Dose Limiting Toxicities of MLN4924 (Pevonedistat) — 1; 2 Participants
Phase 1 N=37 Safety and Pharmacokinetics of Two Vaginal Film Formulations Containing the Integrase Inhibitor MK-2048
Pharmacokinetics · Safety
Primary: Number of Participants With Grade 2 or Higher Adverse Events — 2; 5 Participants — p=.025
Phase 1 N=20 A Treatment Study for Premenstrual Syndrome (PMS)
Premenstrual Syndrome · Menstruation Disturbances
Primary: Mean Beck Depression Inventory Score — 2.6; 3.0; 5.3; 3.6 score on a scale
Phase 1 N=13 Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Non Small Cell Lung Cancer · Urothelial Carcinoma · Malignant Melanoma
Primary: Adverse Events Evaluated by CTCAE 4.0 — 1; 7; 2; 0 Participants
Phase 1 N=93 Differential Responses to Drugs and Sweet Tastes
Bipolar II Disorder
Primary: Change in Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ). — 18.88…
Phase 1 N=25 Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults
Influenza
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H10ssF-6473 Product Administration — 3; 9; 5; 17 Participants
Phase 1 N=23 Differences in Cannabis Impairment and Its Measurement Due to Route of Administration
Behavioral Pharmacology of Cannabis
Primary: Tetrahydrocannabinol (THC) Concentration in Blood — 0; 1.78; 3.06; 0 ng/ml
Phase 1 N=12 A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia
Acute Myeloid Leukemia
Primary: Time (Days) to Transfusion-independent Platelet Recovery (Platelet Counts Values ≥ 20,000/μL and ≥ 50,000/μL Without a Platelet Transfusion) — 21.3; 23.1 days
Phase 1 N=32 A Clinical Study of the HIV Drug CPT31 in Healthy Volunteers
HIV Infections
Primary: Adverse Events — 0; 0; 0; 0 participants experiencing adverse events